# SH2D1A Gene: Structure, Function, and Clinical Significance
## Key Takeaways
- SH2D1A encodes the SLAM-associated protein (SAP), a crucial intracellular adaptor molecule predominantly expressed in lymphocytes, essential for modulating signaling downstream of SLAM family immune receptors.
- Loss-of-function mutations in SH2D1A cause X-linked lymphoproliferative disease type 1 (XLP-1), characterized by severe immune dysregulation, extreme susceptibility to Epstein-Barr virus (EBV) infection, hemophagocytic lymphohistiocytosis (HLH), and lymphoma.
- SAP's unique "three-pronged" binding mechanism, involving phosphotyrosine recognition, specificity-conferring residues, and hydrophobic interactions, allows high-affinity binding to SLAM receptors, enabling it to both inhibit phosphatases and recruit Src family kinases.
- Defective SAP function impairs NK cell cytotoxicity and T-cell/B-cell collaboration, leading to uncontrolled EBV replication and the characteristic immunodeficiency and hyperinflammatory responses seen in XLP-1.
- Hematopoietic stem cell transplantation (HSCT) is the primary curative treatment for XLP-1, with gene therapy approaches utilizing lentiviral vectors or gene editing technologies showing promise for restoring SAP expression.
---
## Executive Summary & Key Metadata
The SH2D1A gene (SH2 Domain Containing 1A) encodes the SLAM-associated protein (SAP), a small intracellular adaptor molecule composed almost entirely of a single Src Homology 2 (SH2) domain. SAP is a critical modulator of signal transduction downstream of the Signaling Lymphocyte Activation Molecule (SLAM) family of immune receptors. It is expressed predominantly in T lymphocytes, natural killer (NK) cells, invariant NKT (iNKT) cells, and some B-cell subsets. Loss-of-function mutations in SH2D1A cause X-linked lymphoproliferative disease type 1 (XLP-1), a primary immunodeficiency characterized by severe immune dysregulation, extreme susceptibility to Epstein-Barr virus (EBV) infection, hemophagocytic lymphohistiocytosis (HLH), dysgammaglobulinemia, and lymphoma. Beyond its canonical role in immunity, recent evidence implicates SH2D1A in the progression of various cancers, including T-cell acute lymphoblastic leukemia (T-ALL) and hepatocellular carcinoma (HCC) [1][2].
| **Metadata Field** | **Value** |
| :--- | :--- |
| **HGNC Symbol** | SH2D1A |
| **UniProt Accession** | O60880 |
| **Representative PDB ID** | 1KA6 (and others, see Section 2) |
| **Chromosomal Locus** | Xq25 (GRCh38: X:123,475,318-123,499,811) |
| **Primary Molecular Function** | SH2 domain-containing adaptor protein; signal transduction modulator for SLAM family receptors |
| **Disease & Pathology Associations** | X-linked lymphoproliferative disease type 1 (XLP-1); Hemophagocytic lymphohistiocytosis (HLH); B-cell lymphoma; T-ALL; Hepatocellular carcinoma; Common variable immunodeficiency (CVID)-like phenotypes |
---
## 1. Genomic Locus, Chromosomal Organization & Isoforms
### 1.1 Chromosomal Localization and Gene Structure
The SH2D1A gene is located on the long (q) arm of the X chromosome at cytogenetic band Xq25. The gene spans approximately 24.5 kilobases (kb) of genomic DNA. The reference genome assembly (GRCh38) places the gene between coordinates 123,475,318 and 123,499,811 on the forward strand. The gene consists of four exons, with the protein-coding sequence distributed across exons 1 through 4. The intronic regions are notably large, with intron 1 being particularly extensive, which has implications for transcriptional regulation and splicing [3][4][5].
The genomic organization is as follows:
- **Exon 1:** Contains the 5' untranslated region (UTR) and the translation initiation codon (ATG). The promoter region and key regulatory elements are located upstream of this exon.
- **Exon 2:** Encodes the N-terminal portion of the SH2 domain, including the crucial phosphotyrosine (pTyr) binding pocket.
- **Exon 3:** Encodes the central region of the SH2 domain, including residues involved in the unique "three-pronged" binding mechanism.
- **Exon 4:** Encodes the C-terminal portion of the SH2 domain and the 3' UTR.
### 1.2 Promoter Architecture and Transcriptional Regulation
The promoter region of SH2D1A lacks a canonical TATA box but is rich in GC content, a feature common to housekeeping and tightly regulated immune genes. Transcriptional regulation is complex and cell-lineage specific, controlled by a combination of proximal promoter elements and distal enhancer regions [6][7].
Key regulatory features include:
- **Super-Enhancer Elements:** Recent research has identified SH2D1A as a super-enhancer-regulated gene. Super-enhancers are large clusters of enhancers that drive high-level expression of genes defining cell identity. In T-ALL, a super-enhancer at the SH2D1A locus drives its aberrant overexpression, contributing to leukemogenesis [1].
- **Methylation Status:** The promoter region of SH2D1A exhibits differential methylation patterns that correlate with cell lineage-specific expression. In cells where the gene is actively transcribed (e.g., T cells, NK cells), the promoter is hypomethylated. Conversely, in non-expressing cells (e.g., fibroblasts, B-cell lines), the promoter is hypermethylated, leading to transcriptional silencing [6]. This epigenetic control is a primary determinant of its restricted expression pattern.
- **Transcription Factor Binding Sites:** The promoter and enhancer regions contain binding sites for multiple transcription factors critical for lymphocyte development and function. These include members of the ETS family, RUNX1, and GATA-3, among others. The combinatorial action of these factors ensures precise temporal and spatial expression of SAP during T-cell and NK-cell differentiation [7].
- **Intronic Regulatory Elements:** A single nucleotide polymorphism (SNP) located in an intronic region (rs34536443, the -346T polymorphism) has been identified as a risk factor for the development of autoimmunity and lymphoproliferation in males with defective Fas function. This suggests that this intronic region may harbor a regulatory element that modulates gene expression levels, potentially influencing the threshold for immune dysregulation [8].
### 1.3 Alternative Splicing and Isoforms
Alternative splicing of SH2D1A generates multiple transcript variants, although the functional significance of many of these remains under investigation.
- **Canonical Isoform (Isoform 1):** This is the predominant and best-characterized isoform, encoding the full-length 128-amino acid SAP protein. It is generated by the splicing of all four exons.
- **Isoform 2 (SH2D1A-2):** This variant uses an alternative acceptor site in exon 2, leading to an in-frame deletion of 8 amino acids (residues 8-15) near the N-terminus. This isoform has been identified in both human and murine cells. Functional studies suggest that this shorter isoform may have altered binding affinities for certain SLAM family receptors, potentially modulating signaling outcomes in a context-dependent manner [9].
- **Other Variants:** Several other minor splice variants have been reported, some of which may be subject to nonsense-mediated decay (NMD). The presence of a complex structural variation leading to exon skipping has been documented in a patient with XLP-1, highlighting the importance of correct splicing for protein function [4]. A novel splicing variant in the intronic region has also been shown to impair SAP expression, leading to agammaglobulinemia [10].
The regulation of splicing is itself a point of control. Mutations that disrupt splice donor or acceptor sites are a common cause of XLP-1, underscoring the critical nature of this process [3][5].
---
## 2. 3D Protein Domain Architecture & Structural Biology
### 2.1 Primary Structure and Domain Organization
The SAP protein is a minimalist adaptor, consisting of a single Src Homology 2 (SH2) domain flanked by short N-terminal and C-terminal extensions. The mature protein is 128 amino acids long, with a molecular weight of approximately 15 kDa. Unlike many other signaling proteins, SAP lacks any catalytic domains, proline-rich regions, or other protein-protein interaction modules. Its entire function is mediated through its SH2 domain, which binds to specific phosphotyrosine-containing motifs on its target receptors.
The domain architecture can be summarized as:
- **N-terminal region (residues 1-5):** A short flexible region preceding the SH2 domain.
- **SH2 Domain (residues 6-104):** The core functional domain, adopting the canonical SH2 fold consisting of a central antiparallel β-sheet flanked by two α-helices.
- **C-terminal region (residues 105-128):** A short tail following the SH2 domain, which contributes to the stability of the domain and may participate in weak interactions.
### 2.2 The SH2 Domain and Its Unique Binding Mechanism
The SH2 domain of SAP is the defining feature of the protein. SH2 domains are modular protein interaction domains that typically recognize phosphotyrosine (pTyr) residues within specific peptide motifs. However, the SAP SH2 domain exhibits a unique and remarkable binding mode that distinguishes it from most other SH2 domains [11][12].
**The "Three-Pronged" Binding Mechanism:**
The interaction between SAP and its primary ligands, the SLAM family receptors, is not solely dependent on pTyr recognition. Instead, it employs a "three-pronged" mechanism that allows for high-affinity binding even to unphosphorylated receptors [12].
1. **Phosphotyrosine Binding Pocket:** The canonical pTyr binding pocket, formed by residues such as Arg32 and Arg55, coordinates the phosphate group of a phosphorylated tyrosine (pTyr) in the cytoplasmic tail of the receptor. This interaction is the primary anchor for binding.
2. **Specificity-Conferring Residues:** A key feature of the SAP SH2 domain is the presence of a threonine at position 53 (Thr53) instead of the more common isoleucine or valine found in other SH2 domains. This Thr53 forms a critical hydrogen bond with the backbone of the peptide ligand, specifically with the residue at the pY+3 position. This interaction provides specificity for the SLAM family consensus motif, which is typically Thr-Ile-Tyr-XXx-Val (TIYXXV).
3. **Hydrophobic Interactions:** The third prong involves a hydrophobic interaction between a unique surface on the SAP SH2 domain and a hydrophobic residue (often valine or isoleucine) at the pY+3 position of the ligand. This interaction, mediated by residues in the βD and βE strands, significantly enhances the binding affinity and contributes to the ability of SAP to bind unphosphorylated receptors.
This unique mechanism allows SAP to bind to its receptors with high affinity (Kd in the low micromolar range) even in the absence of receptor phosphorylation. This is functionally critical, as it allows SAP to constitutively associate with SLAM family receptors and modulate their signaling, rather than being strictly dependent on receptor activation and phosphorylation [13][12].
### 2.3 Structural Basis for Disease-Causing Mutations
The high-resolution structures of the SAP SH2 domain, solved by both X-ray crystallography and NMR spectroscopy, have provided a detailed understanding of how mutations disrupt protein function and cause XLP-1 [14]. Mutations can be broadly classified into several categories based on their structural impact:
- **Mutations that Destabilize the SH2 Domain Fold:** Many missense mutations, such as the common p.Gly93Asp mutation, introduce residues that disrupt the hydrophobic core or create steric clashes, leading to protein misfolding and rapid degradation [15][1].
- **Mutations that Disrupt the Phosphotyrosine Binding Pocket:** Mutations affecting key residues in the pTyr binding pocket, such as Arg32, abolish the ability of SAP to bind to phosphorylated receptors, abrogating its signaling function.
- **Mutations that Affect the Unique Binding Surface:** Mutations in residues involved in the "three-pronged" binding mechanism, such as Thr53, reduce the binding affinity for SLAM family receptors, impairing the ability of SAP to modulate their signaling [12].
- **Nonsense and Frameshift Mutations:** These mutations typically result in a truncated protein that lacks critical structural elements and is non-functional. They often lead to a complete loss of SAP expression [2][3].
### 2.4 Interactive 3D Visualization
To explore the three-dimensional structure of the SAP SH2 domain and visualize the impact of pathogenic mutations, an interactive 3D visualizer is available. This tool allows for the manipulation of the protein structure, highlighting key residues, secondary structure elements, and ligand-binding sites.
[Interactive 3D Protein Visualizer: Load SH2D1A (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O60880)
---
## 3. Cellular Signaling Pathways & Molecular Function
### 3.1 The SLAM Family of Receptors
SAP functions as a critical adaptor protein for the SLAM family of immune receptors. This family includes SLAM (CD150), 2B4 (CD244), CD84, Ly9 (CD229), NTB-A (SF2000), and CRACC (CS1). These receptors are expressed on various hematopoietic cells and play diverse roles in immune regulation, including T-cell activation, NK cell cytotoxicity, and B-cell antibody production. The cytoplasmic tails of these receptors contain one or more copies of the immunoreceptor tyrosine-based switch motif (ITSM), with the consensus sequence Thr-Ile-Tyr-xx-Val (TIYXXV). This ITSM is the docking site for SAP [4][1].
### 3.2 The Dual Functional Role of SAP
SAP exerts its effects on SLAM family signaling through two distinct, non-mutually exclusive mechanisms [13]:
1. **Inhibition of Phosphatase Recruitment:** In the absence of SAP, the ITSM of SLAM family receptors can be bound by SH2 domain-containing protein tyrosine phosphatases, such as SHP-2 (PTPN11) and SHP-1 (PTPN6). These phosphatases dephosphorylate the receptor and downstream signaling molecules, acting as negative regulators of signaling. SAP, by binding to the same ITSM with higher affinity, competitively displaces SHP-1/SHP-2, thereby preventing this inhibitory signal. This "shield" function allows for the propagation of activating signals downstream of the receptor [11][13].
2. **Recruitment of Src Family Kinases:** SAP can also act as a positive adaptor by recruiting the Src family kinase FynT to the receptor complex. The SAP SH2 domain binds to the ITSM, while a second, non-SH2 binding site on SAP interacts with the SH3 domain of FynT. This interaction brings FynT into proximity with the receptor, allowing it to phosphorylate the ITSM and other downstream substrates, thereby initiating an activating signaling cascade. This is a unique "two-sided" role for an SH2 domain-containing protein [13][12].
### 3.3 Downstream Signaling Pathways
The engagement of SAP with SLAM family receptors triggers a cascade of downstream signaling events that are essential for proper immune function.
**T-cell Signaling:**
In CD4+ T cells, SAP is crucial for the function of T follicular helper (Tfh) cells. SAP-mediated signaling downstream of SLAM and Ly108 is required for the stable adhesion between T cells and B cells, a process essential for the formation and maintenance of germinal centers. This interaction is critical for T-cell-dependent B-cell activation, antibody class switching, and the generation of high-affinity antibodies and memory B cells [5][6]. Without SAP, Tfh cells cannot provide adequate help to B cells, leading to the humoral immunodeficiency and dysgammaglobulinemia seen in XLP-1 patients [7][6].
**NK Cell Signaling:**
In NK cells, SAP interacts with 2B4 (CD244). Ligation of 2B4 on NK cells leads to the recruitment of SAP, which then activates downstream signaling pathways, including the PI3K pathway, leading to NK cell activation and cytotoxicity [8]. In the absence of SAP, 2B4 signaling is converted from an activating to an inhibitory signal, as SHP-1 is recruited instead. This functional switch explains the defective NK cell cytotoxicity observed in XLP-1 patients, which contributes to the inability to control EBV infection [8][9].
**NKT Cell Development:**
SAP is absolutely required for the development of invariant NKT (iNKT) cells. The interaction of developing thymocytes with SLAM family receptors on other thymocytes, mediated by SAP, provides a critical signal for the positive selection of iNKT cells. In the absence of SAP, iNKT cells fail to develop, leading to a complete absence of this important immunoregulatory cell population. This deficiency contributes to the immune dysregulation seen in XLP-1 [5].
**NF-κB Activation:**
SAP has been shown to associate with p62dok (Dok1) and activate the NF-κB pathway. This interaction may be important for the survival and proliferation of lymphocytes following receptor engagement [10].
### 3.4 Protein-Protein Interaction Network
SAP is a central node in a well-defined protein-protein interaction network. Key interactions include:
- **SLAM (CD150):** High-affinity interaction, critical for T-cell and NKT-cell function.
- **2B4 (CD244):** Interaction in NK cells, essential for activating cytotoxicity.
- **Ly9 (CD229) and CD84:** Interactions involved in T-cell and B-cell regulation.
- **NTB-A:** Interaction involved in NK cell and T-cell function.
- **FynT:** A Src family kinase recruited by SAP to phosphorylate downstream substrates.
- **SHP-2 (PTPN11):** A phosphatase that SAP competes with for binding to ITSM motifs.
- **Dok1 (p62dok):** An adaptor protein that associates with SAP and is involved in NF-κB activation [10].
```mermaid
sequenceDiagram
participant TCR as "T Cell Receptor"
participant SLAM as "SLAM Family Receptor"
participant SAP as "SAP (SH2D1A)"
participant FYN as "FynT Kinase"
participant SHP as "SHP-1/2 Phosphatase"
participant PI3K as "PI3K Pathway"
participant NFKB as "NF-κB Pathway"
Note over SLAM: Receptor engagement (e.g., SLAM, 2B4)
SLAM->>SAP: Binds to ITSM (pTyr or unphosphorylated)
alt SAP Present (Normal)
SAP->>FYN: Recruits FynT via SH3 domain
FYN->>SLAM: Phosphorylates downstream substrates
FYN->>PI3K: Activates PI3K signaling (in NK cells)
FYN->>NFKB: Activates NF-κB pathway
Note over PI3K,NFKB: Cell activation, cytotoxicity, cytokine production
else SAP Absent (XLP-1)
SLAM->>SHP: Recruits SHP-1/2 to ITSM
SHP->>SLAM: Dephosphorylates receptor and substrates
Note over SHP: Inhibitory signal, cell dysfunction
end
```
---
## 4. Pathogenic Hotspot Mutations & Clinical Differentials
### 4.1 The Spectrum of SH2D1A Mutations
Mutations in SH2D1A are the cause of X-linked lymphoproliferative disease type 1 (XLP-1). Over 100 different disease-causing mutations have been identified, distributed throughout the gene. These include missense, nonsense, frameshift, splice-site, and whole-exon or whole-gene deletions. There is no single predominant "hotspot" mutation, but rather a wide spectrum of private mutations found in individual families [11][12].
### 4.2 Classification of Pathogenic Variants
- **Missense Mutations:** These are single amino acid substitutions that often disrupt the structural integrity of the SH2 domain or its binding surfaces. Examples include:
- **p.Gly93Asp:** A recurrent mutation that introduces a charged residue into the hydrophobic core, destabilizing the protein fold and leading to its degradation [15][1].
- **p.Thr53Ile:** A mutation in the key specificity-conferring residue, disrupting the "three-pronged" binding mechanism and reducing affinity for SLAM receptors [12].
- **p.Arg32Gln:** A mutation in the phosphotyrosine binding pocket, abolishing the ability to bind phosphorylated ligands [1].
- **Nonsense Mutations:** These introduce a premature stop codon, leading to a truncated, non-functional protein. They often result in a complete loss of SAP expression due to nonsense-mediated decay [2].
- **Frameshift Mutations:** Insertions or deletions that shift the reading frame, typically leading to a premature stop codon and a non-functional protein [3].
- **Splice-Site Mutations:** Mutations in the consensus donor or acceptor splice sites can lead to exon skipping, intron retention, or the use of cryptic splice sites. This often results in an aberrant mRNA transcript that is either degraded or encodes a non-functional protein [3][4][5][10].
- **Large Deletions:** Deletions of one or more exons or the entire gene have also been reported [13].
### 4.3 Clinical Phenotypes and Differentials
The clinical presentation of XLP-1 is highly variable, even within families carrying the same mutation. The major phenotypes include:
- **Hemophagocytic Lymphohistiocytosis (HLH):** This is the most common and most severe presentation, often triggered by EBV infection. It is characterized by an uncontrolled hyperinflammatory state with fever, hepatosplenomegaly, cytopenias, and elevated ferritin. HLH is frequently fatal if not treated promptly [2][3][14][15].
- **Dysgammaglobulinemia/Hypogammaglobulinemia:** Many patients develop low levels of immunoglobulins, leading to increased susceptibility to bacterial infections. This can be the presenting feature and can mimic Common Variable Immunodeficiency (CVID) [1][2][3].
- **Lymphoma:** Patients with XLP-1 have a markedly increased risk of developing B-cell lymphomas, particularly Burkitt lymphoma. These lymphomas can occur in the absence of EBV infection [4][5][6].
- **Fulminant Infectious Mononucleosis (FIM):** A severe, often fatal, immune response to primary EBV infection.
- **Atypical Presentations:** Increasingly, atypical presentations are being recognized, including:
- **Neurological symptoms:** Meningoencephalitis, demyelinating lesions, and cerebrovascular injury can be the initial manifestation, even in EBV-naïve patients [7][8][9].
- **Autoimmune manifestations:** Immune cytopenias, vasculitis, and other autoimmune phenomena can occur [8][10].
- **Skin lesions:** A subset of patients presents with characteristic skin lesions [13].
- **Aplastic Anemia:** Profoundly decreased SAP expression has been observed in aplastic anemia, suggesting a potential link [11].
### 4.4 Genotype-Phenotype Correlation
While the clinical phenotype is highly variable, some general correlations can be made. Mutations that completely abolish SAP expression (e.g., large deletions, nonsense mutations) tend to be associated with a more severe and earlier-onset disease. In contrast, missense mutations that allow for residual protein expression and function may lead to a milder or later-onset phenotype. Somatic reversion, where a second-site mutation in a somatic cell restores the reading frame and protein function, has been documented and can lead to a milder clinical course [12].
---
## 5. Host-Pathogen & Viral Interactions
### 5.1 Epstein-Barr Virus (EBV)
The most significant host-pathogen interaction involving SH2D1A is with Epstein-Barr virus (EBV). EBV is a ubiquitous human gamma-herpesvirus that establishes lifelong latent infection in B cells. In healthy individuals, EBV infection is controlled primarily by cytotoxic T cells and NK cells. The immune response to EBV is critically dependent on SAP.
In the absence of functional SAP, the immune system fails to control EBV infection, leading to the severe clinical manifestations of XLP-1. The mechanisms are multifaceted:
- **Impaired T-cell and NK-cell Cytotoxicity:** SAP is required for the activating signal downstream of 2B4 on NK cells and cytotoxic T cells. Without SAP, 2B4 becomes an inhibitory receptor, and the ability of these cells to kill EBV-infected B cells is severely compromised [8][9].
- **Defective T-cell/B-cell Collaboration:** SAP is essential for Tfh cell function and the formation of germinal centers. Without SAP, T cells cannot provide adequate help to B cells, leading to a failure to generate a robust antibody response against EBV [5][6].
- **Uncontrolled B-cell Proliferation:** EBV is a potent B-cell mitogen. In the absence of an effective T-cell response, EBV-infected B cells can proliferate unchecked, leading to the development of B-cell lymphomas [4][6].
The interaction between EBV and SAP is so central that the severity of XLP-1 is often correlated with the timing and outcome of primary EBV infection. Many patients are diagnosed after a severe primary EBV infection that triggers HLH [13][14][15].
### 5.2 Other Viral Infections
While EBV is the most common trigger, other viral infections can also precipitate severe disease in XLP-1 patients. These include:
- **Lymphocytic Choriomeningitis Virus (LCMV):** A case report documented a patient with XLP-1 whose disease was triggered by LCMV infection [1].
- **Other Herpesviruses:** Severe infections with cytomegalovirus (CMV) and other herpesviruses have also been reported.
### 5.3 Viral Manipulation of SH2D1A Expression
The relationship between EBV and SH2D1A is complex. EBV infection of B cells can alter the expression of SH2D1A. In Burkitt lymphoma cell lines, SH2D1A expression is restricted to EBV-positive group I lines (which have a more "resting" phenotype) and is downregulated upon immunoblastic transformation. This suggests that EBV may modulate SH2D1A expression to promote B-cell survival and proliferation [2][3].
---
## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors
### 6.1 Current Treatment Paradigms
The primary treatment for XLP-1 is hematopoietic stem cell transplantation (HSCT), which is the only curative option. HSCT replaces the defective immune system with a functional one, restoring SAP expression in all hematopoietic lineages [7][4]. The success of HSCT is highly dependent on the patient's clinical status at the time of transplantation, with better outcomes in patients who have not yet developed severe complications like HLH.
### 6.2 Gene Therapy
Gene therapy is a promising alternative for patients who lack a suitable donor or who are not candidates for HSCT.
- **Lentiviral Vector-Mediated Gene Addition:** This approach involves harvesting the patient's own hematopoietic stem cells (HSCs) or T cells, transducing them ex vivo with a lentiviral vector encoding a functional SH2D1A gene, and then infusing the corrected cells back into the patient. Proof-of-concept studies have shown that gene-corrected T cells can restore humoral and cytotoxic defects in XLP-1 [5][6][7]. A regulated lentiviral vector (XLP-SMART LV) is being developed to express SAP at therapeutic levels specifically in T, NK, and NKT cells [8].
- **Targeted Gene Addition:** More precise gene editing approaches, such as CRISPR-Cas9 or zinc-finger nucleases (ZFNs), are being explored to insert a corrective copy of the SH2D1A gene into a specific "safe harbor" locus, such as the AAVS1 site. This approach aims to achieve stable, long-term expression of SAP from a defined genomic location [9][10].
### 6.3 Small-Molecule Inhibitors and Targeted Therapy
There are currently no FDA-approved small-molecule inhibitors that directly target SAP. However, the emerging role of SH2D1A in cancer has opened new avenues for therapeutic intervention.
- **Targeting SH2D1A in T-ALL:** The finding that SH2D1A is a super-enhancer-regulated gene that promotes T-ALL progression by activating CHI3L2 suggests that targeting this pathway could be a novel therapeutic strategy. This could involve inhibiting the super-enhancer machinery (e.g., with BET inhibitors like JQ1) or targeting downstream effectors like CHI3L2 [1].
- **Targeting SH2D1A in HCC:** Overexpression of SH2D1A in hepatocellular carcinoma (HCC) is associated with cancer progression and immune cell infiltration. This suggests that SH2D1A could be a potential therapeutic target in HCC, although the specific strategies are still in the early stages of investigation [2].
- **Immunomodulatory Therapy:** For the management of HLH, immunomodulatory agents such as etoposide, dexamethasone, and cyclosporine A are used to suppress the hyperinflammatory state. Rituximab, an anti-CD20 monoclonal antibody, is often used to deplete B cells and reduce the viral load in EBV-driven disease.
---
## 7. Bioinformatic Resources & Database Accessions
The following table provides key database accessions and resources for SH2D1A.
| **Database** | **Identifier / Link** |
| :--- | :--- |
| **NCBI Gene** | [Gene ID: 4068](https://www.ncbi.nlm.nih.gov/gene/4068) |
| **Ensembl** | [ENSG00000183978](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000183978) |
| **UniProt** | [O60880](https://www.uniprot.org/uniprotkb/O60880/entry) |
| **RCSB PDB** | [1KA6](https://www.rcsb.org/structure/1KA6), [1M27](https://www.rcsb.org/structure/1M27), [2D1T](https://www.rcsb.org/structure/2D1T) |
| **OMIM** | [11](https://www.omim.org/entry/308240) |
| **ClinVar** | [SH2D1A](https://www.ncbi.nlm.nih.gov/clinvar/?term=SH2D1A%5Bgene%5D) |
| **Gene Ontology (GO)** | [GO:0005737 (cytoplasm)](https://www.ebi.ac.uk/QuickGO/term/GO:0005737), [GO:0005102 (signaling receptor binding)](https://www.ebi.ac.uk/QuickGO/term/GO:0005102), [GO:0045087 (innate immune response)](https://www.ebi.ac.uk/QuickGO/term/GO:0045087) |
| **STRING** | [SH2D1A (Homo sapiens)](https://string-db.org/network/9606.ENSP00000355237) |
| **BioGRID** | [SH2D1A](https://thebiogrid.org/gene/112358) |
---
## Related Clinical & Scientific Guides
* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)
## References
[1] Jiao, W., Yu, J., Zhang, Z., et al. (2025). The super-enhancer regulatory gene SH2D1A promotes the progression of T cell acute lymphoblastic leukemia by activating CHI3L2. *Cellular Signalling*. URL: https://www.semanticscholar.org/paper/f16a9defed6eb5d115a7db82d36c782bd41be583
[2] Dang, W., Duan, Y., Zhou, C. J., et al. (2025). [Long-term follow-up of a novel SH2D1A gene mutation associated disease: a case report]. *Zhonghua nei ke za zhi*. URL: https://www.semanticscholar.org/paper/bc3288a0d2bab6e5e3866d94ff3e00643db38d24
[3] Wang, Y., Wang, Y., Lu, W., et al. (2022). Potential pathogenic mechanism of type 1 X-linked lymphoproliferative syndrome caused by a mutation of SH2D1A gene in an infant: A case report. *Medicine*. URL: https://www.semanticscholar.org/paper/fec08c852b813dfc32a1acd8046b191d91360574
[4] Sharapova, S., Fedorova, A., Pashchenko, O., et al. (2017). Novel Mutations in SH2D1A Gene in X-linked Lymphoproliferative Syndrome, Diagnosed After B-Cell Non-Hodgkin Lymphoma. *Journal of pediatric hematology/oncology*. URL: https://www.semanticscholar.org/paper/1228d3bc070cf5ebb8acc5f9b363dc285e6b8086
[5] Zhou, S., Ma, H., Gao, B., et al. (2017). Characterization of a novel disease-causing mutation in exon 1 of SH2D1A gene through amplicon sequencing: a case report on HLH. *BMC Medical Genetics*. URL: https://www.semanticscholar.org/paper/fd77b7f907637cd07efe2f89f68910e40d348e8a
[6] (2020). SH2D1A Gene. *Definitions*. URL: https://www.semanticscholar.org/paper/0fad61d28e5b47d1ea79e89322034f9c9bfb2b53
[7] (2020). SH2D1A Gene Mutation. *Definitions*. URL: https://www.semanticscholar.org/paper/873bfe8ab695d907ebdcbf8501105273f03c9b93
[8] Koochakzadeh, L., Hosseinverdi, S., Hedayat, M., et al. (2015). Study of SH2D1A gene mutation in paediatric patients with B-cell lymphoma. *Allergologia et Immunopathologia*. URL: https://www.semanticscholar.org/paper/010df4ac4e1916f0891c3934bb7ddf356766c0f2
[9] de la Varga-Martínez, R., Mora-López, F., García-Cuesta, D., et al. (2017). X-linked Lymphoproliferative Disease Type 1 in a Patient With the p.Gly93Asp SH2D1A Gene Mutation and Hemophagocytic Lymphohistiocytosis. *Journal of pediatric hematology/oncology*. URL: https://www.semanticscholar.org/paper/cc8981f6c0263e63158cf5d067b652924469248a
[10] Czar, M., Kersh, E., Mijares, L. A., et al. (2001). Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. *Proceedings of the National Academy of Sciences of the United States of America*. URL: https://www.semanticscholar.org/paper/c7adc3d9b2b4200fe4513dac3f3d52988da94a97
[11] Morra, M., Silander, O., Calpe, S., et al. (2001). Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome. *Blood*. URL: https://www.semanticscholar.org/paper/8c85c46ade6d27baee0c28ac305a762682b11c6e
[12] Soresina, A., Lougaris, V., Giliani, S., et al. (2002). Mutations of the X-linked lymphoproliferative disease gene SH2D1A mimicking common variable immunodeficiency. *European Journal of Pediatrics*. URL: https://www.semanticscholar.org/paper/b6d89ab8662e339cc3ad2a9ee2b27a679a4b8204
[13] Tóth, B., Soltész, B., Gyimesi, E., et al. (2014). Severe XLP Phenotype Caused by a Novel Intronic Mutation in the SH2D1A Gene. *Journal of Clinical Immunology*. URL: https://www.semanticscholar.org/paper/0d741fc186aa4ee3e15bd610b7e706b981ff9201
[14] Boggio, E., Melensi, M., Bocca, S., et al. (2012). The -346T polymorphism of the SH2D1A gene is a risk factor for development of autoimmunity/lymphoproliferation in males with defective Fas function. *Human Immunology*. URL: https://www.semanticscholar.org/paper/ccd54cb5a86d6eabe229e6ed0bf56fa666655c27
[15] Parolini, O., Weinhäusel, A., Kagerbauer, B., et al. (2003). Differential methylation pattern of the X-linked lymphoproliferative (XLP) disease gene SH2D1A correlates with the cell lineage-specific transcription. *Immunogenetics*. URL: https://www